MEI Pharma is a clinical-stage pharmaceutical company headquartered in San Diego, CA, focused on developing novel and differentiated cancer therapies to improve patient outcomes. They aim to overcome known resistance mechanisms by evaluating drug candidates in combinations with standard-of-care therapies. Their portfolio includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor.

MEI Pharma's team consists of experienced professionals, including Dr. Richard Ghalie, a hematologist and oncologist with over 25 years of drug development experience, and Mr. Justin (Jay) File, the Chief Financial Officer with 30 years of experience in accounting and finance.

The company is committed to providing improved patient benefit and addresses clear medical needs. With a focus on hematologic malignancies and solid tumors, MEI Pharma is dedicated to bringing effective cancer therapies to those in need through their research, development, and clinical trials